1-14 of 14
Keywords: Tyrosine kinase inhibitors
Close
Sort by
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2023) 101 (11): 685–694.
Published Online: 25 April 2023
...)-tyrosine kinase inhibitors (TKIs) are the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) with sensitive EGFR mutations. The Glasgow prognostic score (GPS) is an inflammation-assessing score based on C-reactive protein and albumin concentrations. Information regarding...
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2014) 87 (3): 133–147.
Published Online: 08 July 2014
...David Cella; Cindy J. Nowinski; Olga Frankfurt Patients with chronic myeloid leukemia (CML) in chronic phase are living longer on BCR-ABL1 tyrosine kinase inhibitor (TKI) therapy, placing emphasis on issues related to symptom burden and quality of life (QoL). Furthermore, the potential for adverse...
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2012) 83 (5): 248–256.
Published Online: 04 September 2012
... likely to present the EGFR wild type (WT; p = 0.033). Response to EGFR-tyrosine kinase inhibitor (TKI) was similar between patients with EML4-ALK rearrangement and EGFR mutation (33.3 vs. 46.9%, p = 0.451), but progression-free survival (PFS) was inferior compared to those with EGFR mutation (2.1 vs. 8.8...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2012) 82 (6): 333–340.
Published Online: 02 June 2012
... progressed most often rapidly. Receptor tyrosine kinase inhibitors (rTKIs) have significantly altered the clinical course of mRCC. As of today, three rTKIs, namely sorafenib, sunitinib and pazopanib, have been approved by regulatory authorities and are used routinely [ 2,3,4 ]. Next-generation rTKIs like...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2010) 77 (6): 400–410.
Published Online: 02 February 2010
... to cancer, ErbB signaling has also been implicated in cardiovascular and neurodegenerative diseases. Conversely, inhibition of ErbB pathways with targeted agents, such as monoclonal antibodies (MoAbs) or tyrosine kinase inhibitors (TKIs), blocks cell cycle progression, inhibits the production of pro...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2009) 77 (1): 1–11.
Published Online: 12 May 2009
.... Currently, anti-angiogenic molecularly targeted therapies, including administration of monoclonal antibodies or tyrosine kinase inhibitors (TKIs), are being increasingly adopted for treating GBMs. This approach is based on the ability of anti-VEGFRs monoclonal antibodies to decrease vascular permeability...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2009) 76 (5): 350–354.
Published Online: 24 March 2009
...Kaja Zimmermann; Alexander Schmittel; Ursula Steiner; Anne Marie Asemissen; Maren Knoedler; Eckhard Thiel; Kurt Miller; Ulrich Keilholz Background: Sorafenib and sunitinib are tyrosine kinase inhibitors with largely overlapping specificities, approved for the treatment of metastatic renal-cell...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2008) 74 (1-2): 1–6.
Published Online: 09 June 2008
... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Ovarian cancer Anti-angiogenic agents Bevacizumab Epidermal growth factor inhibitors Tyrosine kinase inhibitors Ovarian cancer is recognized to be one of the most...